A phase 1/1b study of RXDX-105, an oral RET and BRAF inhibitor, in patients with advanced solid tumorsAlexander Drilon,F. Marwan,Siqing Fu,Manish R. Patel,A.J. Olszanski,Albert C. Lockhart,S.V. Liu,Lyudmila Bazhenova,T. Seery,P. Nikolinakos,R. Patel, J.W. Oliver,Pratik S. Multani,D. WangEUROPEAN JOURNAL OF CANCER(2016)引用 1|浏览15暂无评分AI 理解论文溯源树样例生成溯源树,研究论文发展脉络Chat Paper正在生成论文摘要